Stay updated on Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial
Sign up to get notified when there's something new on the Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial page.

Latest updates to the Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial page
- Check5 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2; removed the funding-status notice and Revision: v3.4.1.SummaryDifference0.5%

- Check41 days agoChange DetectedThe page displays a government funding lapse notice and a site status message. The release note updates from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check48 days agoChange DetectedAdded a glossary toggle and updated QC metadata to revision 3.4.0 (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data').SummaryDifference0.2%

- Check62 days agoChange DetectedA revision note shows the page version updated from v3.3.3 to v3.3.4, with no changes to study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedA new Locations section appears with Ontario as a site for the study. The footer shows Revision: v3.3.3 and removes the old Ontario Locations link as well as the HHS Vulnerability Disclosure link.SummaryDifference0.2%

Stay in the know with updates to Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Empagliflozin and Beta-cell Preservation in GDM Women Clinical Trial page.